CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price objective on CASI Pharmaceuticals from $12.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, May 15th.

CASI Pharmaceuticals Price Performance

CASI stock opened at $2.86 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 5.05 and a quick ratio of 3.25. The business has a 50 day simple moving average of $2.96 and a 200-day simple moving average of $4.65. The firm has a market capitalization of $38.32 million, a PE ratio of -1.25 and a beta of 0.60. CASI Pharmaceuticals has a 1 year low of $1.90 and a 1 year high of $8.48.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.66). CASI Pharmaceuticals had a negative net margin of 105.76% and a negative return on equity of 110.11%. The company had revenue of $3.41 million during the quarter. Equities research analysts anticipate that CASI Pharmaceuticals will post -2.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Howland Capital Management LLC bought a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned about 0.30% of CASI Pharmaceuticals at the end of the most recent reporting period. 22.23% of the stock is owned by institutional investors.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.